Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Dragnev

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Expert Opinion on Pharmacotherapy|May 8, 2010
Pemetrexed in advanced non-small-cell lung cancerAlexander D Fuld, Konstantin H Dragnev, James R Rigas
Meat Science|November 8, 2011
Comparative study of buffalo meat and beefC Valin, A Pinkas, H Dragnev, et al.
Frontiers in Cell and Developmental Biology|May 11, 2023
Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitationsKonstantin H Dragnev, Christo P C Dragnev, Ronald A Lubet
Annals of the New York Academy of Sciences|January 25, 2002
Cyclin proteolysis as a retinoid cancer prevention mechanismK H Dragnev, S J Freemantle, M J Spinella, et al.
Clinical Pharmacology : Advances and Applications|February 19, 2019
Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapyWilliam G North, Fuli Liu, Konstantin H Dragnev, et al.
Cancer Treatment Reviews|June 18, 2013
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patientsMonic Roengvoraphoj, Gregory J Tsongalis, Konstantin H Dragnev, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung CancerIvy Riano, Inas Abuali, Aditya Sharma, et al.
Clinical Lung Cancer|January 15, 2004
The role of docetaxel in nonplatinum-based combination chemotherapy for non-small-cell lung cancerW Jeffrey Petty, Joerg Rothmann, Konstantin H Dragnev, et al.
Clinical Lung Cancer|February 8, 2005
Nonclassical retinoids and lung carcinogenesisKonstantin H Dragnev, W Jeffrey Petty, Yan Ma, et al.
Expert Opinion on Biological Therapy|October 15, 2011
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancerTrevor J Bayliss, Jeff T Smith, Michael Schuster, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Expert Opinion on Pharmacotherapy|May 8, 2010
Pemetrexed in advanced non-small-cell lung cancerAlexander D Fuld, Konstantin H Dragnev, James R Rigas
Meat Science|November 8, 2011
Comparative study of buffalo meat and beefC Valin, A Pinkas, H Dragnev, et al.
Frontiers in Cell and Developmental Biology|May 11, 2023
Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitationsKonstantin H Dragnev, Christo P C Dragnev, Ronald A Lubet
Annals of the New York Academy of Sciences|January 25, 2002
Cyclin proteolysis as a retinoid cancer prevention mechanismK H Dragnev, S J Freemantle, M J Spinella, et al.
Clinical Pharmacology : Advances and Applications|February 19, 2019
Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapyWilliam G North, Fuli Liu, Konstantin H Dragnev, et al.
Cancer Treatment Reviews|June 18, 2013
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patientsMonic Roengvoraphoj, Gregory J Tsongalis, Konstantin H Dragnev, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung CancerIvy Riano, Inas Abuali, Aditya Sharma, et al.
Clinical Lung Cancer|January 15, 2004
The role of docetaxel in nonplatinum-based combination chemotherapy for non-small-cell lung cancerW Jeffrey Petty, Joerg Rothmann, Konstantin H Dragnev, et al.
Clinical Lung Cancer|February 8, 2005
Nonclassical retinoids and lung carcinogenesisKonstantin H Dragnev, W Jeffrey Petty, Yan Ma, et al.
Expert Opinion on Biological Therapy|October 15, 2011
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancerTrevor J Bayliss, Jeff T Smith, Michael Schuster, et al.
Pageof 9